✦ LIBER ✦

Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up

✍ Scribed by YaZhen Qin; Bin Jiang; Qian Jiang; Hao Jiang; JinLan Li; Yan Zhang; HongHu Zhu; LingDi Li; ShanShan Chen; YanRong Liu; XiaoJun Huang

Book ID: 105989196
Publisher: Springer
Year: 2008
Tongue: English
Weight: 117 KB
Volume: 88
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0548-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib dose escalation to achieve mole

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

✍ F. Stagno; P. Vigneri; V. Del Fabro; S. Stella; M. Massimino; S. Berretta; A. Me 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Peripheral blood progenitor cell collect

Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate

✍ Paolo Perseghin; Carlo Gambacorti-Passerini; Lucia Tornaghi; Maria Dassi; Pietro 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Durable responses in chronic myeloid leu

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

✍ Angelo Michele Carella; Enrica Lerma 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 88 KB

Achievement of complete molecular respon

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Ros 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cas

Patients with chronic myeloid leukemia w

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

✍ Ross, D M; Branford, S; Seymour, J F; Schwarer, A P; Arthur, C; Bartley, P A; Sl 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 354 KB

Patients with chronic myeloid leukemia w

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

✍ Ross, D M; Branford, S; Seymour, J F; Schwarer, A P; Arthur, C; Bartley, P A; Sl 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 354 KB